InflaRx Future Growth

NasdaqGS:IFRX - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1	-60	-20	-28	3
12/31/2025	1	-73	-93	-60	3
12/31/2024	0	-57	N/A	-51	3
9/30/2024	0	-57	-48	-48	N/A
6/30/2024	0	-47	-43	-43	N/A
3/31/2024	0	-41	-42	-42	N/A
12/31/2023	0	-43	-38	-38	N/A
9/30/2023	0	-35	-32	-32	N/A
6/30/2023	N/A	-35	-30	-30	N/A
3/31/2023	N/A	-27	-32	-31	N/A
12/31/2022	N/A	-29	-34	-34	N/A
9/30/2022	N/A	-34	-40	-40	N/A
6/30/2022	N/A	-38	-47	-47	N/A
3/31/2022	N/A	-54	-42	-42	N/A
12/31/2021	N/A	-46	-40	-40	N/A
9/30/2021	N/A	-42	-38	-38	N/A
6/30/2021	N/A	-37	-37	-37	N/A
3/31/2021	N/A	-32	-37	-36	N/A
12/31/2020	N/A	-34	-37	-37	N/A
9/30/2020	N/A	-39	-43	-43	N/A
6/30/2020	N/A	-46	-43	-43	N/A
3/31/2020	N/A	-52	-46	-45	N/A
12/31/2019	N/A	-53	-44	-43	N/A
9/30/2019	N/A	-50	-34	-33	N/A
6/30/2019	N/A	-42	-30	-29	N/A
3/31/2019	N/A	-29	-25	-24	N/A
12/31/2018	N/A	-30	-22	-22	N/A
9/30/2018	N/A	-31	-20	-19	N/A
6/30/2018	N/A	-29	N/A	-18	N/A
3/31/2018	N/A	-31	N/A	-15	N/A
12/31/2017	N/A	-24	N/A	-12	N/A
9/30/2017	N/A	-17	N/A	-10	N/A
6/30/2017	N/A	-15	N/A	-8	N/A
3/31/2017	N/A	-12	N/A	-7	N/A
12/31/2016	N/A	-9	N/A	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IFRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IFRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IFRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IFRX's revenue (65.8% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: IFRX's revenue (65.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IFRX's Return on Equity is forecast to be high in 3 years time

InflaRx Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates fall by 72%

Consensus EPS estimates upgraded to €0.69 loss

Consensus revenue estimates fall by 94%

No longer forecast to breakeven

Consensus revenue estimates fall by 13%

No longer forecast to breakeven

Recent updates

InflaRx N.V. Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

InflaRx N.V. to Report Q3, 2024 Results on Nov 08, 2024

Consensus revenue estimates fall by 72%

New major risk - Financial position

InflaRx N.V. to Report Q2, 2024 Results on Aug 08, 2024

InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely

Inflarx’S Gohibic (Vilobelimab) Selected for First Barda-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (Ards)

InflaRx N.V. Hosts R&D Event Highlighting the Promise of INF904

Consensus EPS estimates upgraded to €0.69 loss

New major risk - Revenue and earnings growth

InflaRx N.V. to Report Q1, 2024 Results on May 08, 2024

InflaRx N.V., Annual General Meeting, Apr 25, 2024

Consensus revenue estimates fall by 94%

No longer forecast to breakeven

InflaRx N.V. to Report Q4, 2023 Results on Mar 21, 2024

InflaRx N.V. Appoints Jan Medina as Head of Investor Relations

Consensus revenue estimates fall by 13%

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

No longer forecast to breakeven

New minor risk - Market cap size

InflaRx N.V. Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Inflarx N.V.'S Marketing Authorization Application (Maa) for Vilobelimab for Treatment of Critically Ill Covid-19 Patients Under Review by European Medicines Agency (Ema)

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates fall by 68%

Forecast breakeven date moved forward to 2024

Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023

Forecast breakeven date moved forward to 2024

Forecast to breakeven in 2025

Consensus revenue estimates increase by 883%, EPS downgraded

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx N.V. Announces Details Related to the Design of its Planned Phase III Study with Vilobelimab in Ulcerative PG

InflaRx N.V. Provides Update on Planned Phase Iii Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of Its Eua Application in Critically Ill Covid-19 Patients

InflaRx N.V. announced that it expects to receive $2.5 million in funding from Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

Consensus revenue estimates increase by 34%

Consensus revenue estimates increase by 34%

InflaRx N.V. Initiates First-In-Human Study with Small Molecule C5ar Inhibitor Inf904

Inflarx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

InflaRx N.V. Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in the Lancet Respiratory Medicine

InflaRx reports Q2 results

InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

InflaRx Receives U.S. Food and Drug Administration Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

InflaRx N.V. Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

No longer forecast to breakeven

Forecast to breakeven in 2024

InflaRx N.V., Annual General Meeting, Apr 28, 2022

Consensus revenue estimates fall by 31%

InflaRx N.V. Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Forecast to breakeven in 2024

InflaRx N.V. Reports That It Has Received an Advice Letter from the U.S. Food and Drug Administration Related to Its Phase Iii Program with Vilobelimab

InflaRx N.V. Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma

InflaRx N.V Announces New Pipeline Program – Oral C5aR Inhibitor

InflaRx N.V. Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa

Our First Look At InflaRx

Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)

Independent Non-Executive Director Lina Ma has left the company

InflaRx N.V. to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks

InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum

Consensus forecasts updated

Inflarx Doses First Patient in Multicenter Phase Ii Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab